Actively Recruiting
Study of GVV858 Alone or Combined With Endocrine Therapy for Advanced HRHER2- Breast Cancer and Other Solid Tumors
Led by Novartis Pharmaceuticals · Updated on 2026-10-29
205
Participants Needed
16
Research Sites
N/A
Total Duration
AI-Summary
What This Trial Is About
This research investigates GVV858 as a single treatment and in combination with endocrine therapies fulvestrant or letrozole for patients with advanced hormone receptor-positive, HER2-negative breast cancer, other solid tumors with CCNE1 amplification, and metastatic castration-resistant prostate cancer. The study is a first-in-human, open-label Phase III trial aiming to understand safety, tolerability, and optimal dosing of GVV858. Participants may receive GVV858 alone or combined with approved endocrine therapies. The Phase I part focuses on dose escalation and safety in three patient groups, with potential expansion by disease type. The Phase II part evaluates GVV858 with fulvestrant in advanced breast cancer patients, including randomized comparison and optional dose optimization. Throughout the study, participants undergo regular monitoring of safety and drug effects up to about two years. This includes tracking adverse events, dose changes, drug levels in the blood, and cancer response measures. The study spans from initial screening, treatment cycles of 28 days, and ongoing assessments to evaluate tolerability and treatment impact.
CONDITIONS
Brief Title
Study of GVV858 as a Single Agent or in Combination With Endocrine Therapy in Patients With HR+/HER2- Breast Cancer and Other Advanced Solid Tumors
Research Team
N
Novartis Pharmaceuticals
N
Novartis Pharmaceuticals
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here